Loading clinical trials...

Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia | Clinical Trials | Clareo Health

RECRUITINGNA

Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia

Intravenous Infusion of Esketamine in Combination With Pregabalin and Duloxetine for Postherpetic Neuralgia

NCT06896994•Beijing Tiantan Hospital

Summary

To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN).

Detailed Description

The investigators aim to investigate whether or not esketamine combined with pregabalin and duloxetine to relieve pain in patients with PHN, and seek a rapid, effective and safe treatment for refractory patients with PHN

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Ages more than 18 years;
•2. Pain present for more than 3 months after healing of a herpes zoster skin rash;
•3. Has an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0= no pain, 10= worst possible pain)；
•4. Failed to respond to or tolerate the effective dose of pregabalin monotherapy.

Exclusion Criteria

•1. Obstructive sleep apnoea syndrome;
•2. Those who receive interventional treatments;
•3. A history of systemic immune diseases, organ transplantation, or cancers;
•4. A history of severe cardiopulmonary, hepatic or renal dysfunction;
•5. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
•6. Currently using monoamine oxidase inhibitors (MAOIs);
•7. Having untreated angle-closure glaucoma;
•8. Those suffering from increased intracranial pressure；
•9. Comorbid hyperthyroidism or phaeochromocytoma;
•10. Suspected or confirmed history of drug abuse;
+3 more criteria

Locations (1)

Beijing Tiantan Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

April 1, 2025

Primary Completion Date

April 1, 2026

Completion Date

May 1, 2026

Last Updated

April 27, 2025

Enrollment

150

ESTIMATED participants

Conditions

Postherpetic Neuralgia

Interventions

esketamine group

DRUG

control group

DRUG

Contacts

Fang Luo, M.D.

CONTACT

+86 13611326978 13611326978@163.com

The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia.

NCT07000409

Postherpetic NeuralgiaChronic Pain+3 more

View study

ACTIVE_NOT_RECRUITING

Relationship Between Serum Vitamin D Levels and Postherpetic Neuralgia.

NCT06232486

Postherpetic Neuralgia

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 27, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia

Inclusion Criteria

Exclusion Criteria

The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia.

Relationship Between Serum Vitamin D Levels and Postherpetic Neuralgia.

Dorsal Root Ganglion Stimulation in Postherpetic Neuropathy

Predictors of Success After Intercostal Nerve Radiofrequency Treatment for Intercostal Neuralgia

Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia

Esketamine Combined With PRF of DRG for Postherpetic Neuralgia